



Lumos Clinical Research Center

Physician-led psychiatry, CNS and cardiometabolic research site, directly across from Good Samaritan Hospital. Our own psychiatry practice feeds enrollment; one team, one record.

98.8%

Retention across recent programs

400%

Of expected enrollment across six recent programs (72 expected, 288 enrolled)

46

Industry-sponsored trials as PI since 2020 (20 active, 26 completed)

22

On-site team; all coordinators internationally trained physicians

8,500 sq ft

Single site, dosing and inpatient rooms, on-site lab

INVESTIGATORS AND TEAM

Principal investigator	Sarbani Maitra, MD. Medical Director; ABPN board certified; CA and TN licensed; DEA Schedule I researcher and II-V; GCP current through Aug 2029
Sub-investigator	Joseph M. Isaacson, MD, FACP, FACR. Board certified in Obesity Medicine; Adjunct Associate Clinical Professor, Stanford; sub-I since 2021
Site leadership	Darya Babina, MD, PhD (Site Director) · Shazia Fayyaz, MD (Study Director)
Staff	8 CRCs (all foreign-trained MDs), 8 research assistants; GCP certification current
Retention	98.8% across recent programs
Languages	English and Spanish on site

OPERATIONS

Start-up	About 2 weeks; single-site decisions, in-house regulatory and budget review; no build-out required
IRB	Central IRB
CTMS / eSource	Aega (in-house); private monitor workspace
Screening	Metabolic and psychiatric assessments in-house
Recruitment	Own patient registry and community; not paid advertising
Phases	Phase II and III; diagnostic and digital therapeutic studies
Therapeutic areas	MDD, GAD, ADHD, bipolar, OCD, PTSD, schizophrenia, panic, social anxiety, autism; obesity, T1D/T2D, GLP-1; migraine, Alzheimer's

ENROLLMENT TRACK RECORD (SIX RECENT PROGRAMS)

INDICATION	EXPECTED	ENROLLED	% OF TARGET
Obesity 1 program	20	107	535%
Social anxiety disorder 2 programs	35	153	437%
Major depressive disorder 2 programs	15	23	153%
Schizophrenia 1 program	2	5	250%

TRIALS AS PI BY INDICATION (2020-2026)

INDICATION	TRIALS
Major depressive disorder	18
Anxiety disorders, incl. social anxiety	7
Pediatric psychiatry	6
Other CNS and diagnostic	5
OCD · Schizophrenia	3 · 3
Panic disorder · Motion sickness	2 · 2
TRD · PTSD within the MDD and other-CNS counts above	3 · 3
Obesity	1

WHY SPONSORS CHOOSE LUMOS

- **Consistently delivered:** every recent sponsor program finished above its contracted target
- **Well-controlled placebo response:** rigorous rater training and patient selection, which shows in the quality of the data a study ends with
- **FDA audited:** highest-enrolling site for an approved drug
- **The population behind our enrollment:** a deep pool of research-naïve patients, new to clinical trials, and a diverse population that supports sponsor diversity goals, with bilingual English and Spanish staff

FACILITY

- **2 dosing rooms · 2 private monitored inpatient rooms**, expandable to 5 · on-site lab, EKG
- **Samples:** ambient centrifuge; -20/-70/-80 °C freezers · **IP:** locked cabinet, Schedule I-V
- **Imaging** (X-ray, CT, MRI, PET-CT, DEXA) two minutes away · **24/7 ED** across the street · free parking